Argan, Inc (AGX) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 12, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2027, filed Sep 2, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the AGX SEC filings page.
Argan, Inc (AGX) reported $1.2B in revenue over the twelve months to Jul 31, 2026, up 29.0% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Argan’s numbers describe a rapidly expanding business where margins and cash generation improved faster than revenue, alongside heavier balance-sheet obligations.
From FY2024 to FY2026, operating margin rose from6.4% to14.3% , showing that recent expansion carried more profit through operations rather than merely adding sales. In FY2026, operating cash flow of$414.7M was about three times net income of$137.8M , a gap that points to working-capital release as an important cash source.
As revenue expanded through FY2026, gross margin recovered to
Total liabilities climbed from
Financial Health Signals
Scored against operating companies for FY2026. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Argan, Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Argan, Inc has an operating margin of 14.3%, meaning the company retains $14 of operating profit per $100 of revenue. This strong profitability earns a score of 70/100, reflecting efficient cost management and pricing power. This is up from 10.1% the prior year.
Argan, Inc's revenue grew 8.1% year-over-year to $944.6M, a solid pace of expansion. This earns a growth score of 89/100.
Argan, Inc has a moderate D/E ratio of 1.57. This balance of debt and equity financing earns a leverage score of 36/100.
Argan, Inc's current ratio of 1.59 indicates adequate short-term liquidity, earning a score of 45/100. The company can meet its near-term obligations, though with limited headroom.
Argan, Inc converts 43.5% of revenue into free cash flow ($410.8M). This strong cash generation earns a score of 95/100.
Argan, Inc earns a strong 29.8% return on equity (ROE), meaning it generates $30 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 84/100. This is up from 24.3% the prior year.
Argan, Inc scores 6.59, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($5.4B) relative to total liabilities ($724.1M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Argan, Inc passes 5 of 8 computable financial strength tests (1 of the nine could not be computed from available data). All 4 profitability signals pass (positive income, cash flow, and earnings quality), no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.
For every $1 of reported earnings, Argan, Inc generates $3.01 in operating cash flow ($414.7M OCF vs $137.8M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Key Financial Metrics
Earnings & Revenue
Argan, Inc generated $384.0M in revenue in Q2 2027. This represents an increase of 61.5% from the same quarter a year earlier. Against the prior quarter it is up 32.0%.
Argan, Inc's EBITDA was $57.5M in Q2 2027, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 87.7% from the same quarter a year earlier. Against the prior quarter it is up 25.0%.
Argan, Inc reported $53.3M in net income in Q2 2027. This represents an increase of 51.1% from the same quarter a year earlier. Against the prior quarter it is up 15.7%.
Argan, Inc earned $3.76 per diluted share (EPS) in Q2 2027. This represents an increase of 50.4% from the same quarter a year earlier. Against the prior quarter it is up 16.0%.
Cash & Balance Sheet
Argan, Inc generated $91.7M in free cash flow in Q2 2027, representing cash available after capex. This represents an increase of 178.7% from the same quarter a year earlier. Against the prior quarter it is down 17.3%.
Argan, Inc held $364.5M in cash as of Q2 2027; long-term debt is not reported for that period.
Argan, Inc paid $0.50 per share in dividends in Q2 2027. This represents an increase of 33.3% from the same quarter a year earlier. It is unchanged from the prior quarter.
Margins & Returns
Argan, Inc's gross margin was 19.3% in Q2 2027, indicating the percentage of revenue retained after direct costs. This is up 0.7 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.7 percentage points.
Argan, Inc's operating margin was 14.8% in Q2 2027, reflecting core business profitability. This is up 2.1 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.8 percentage points.
Argan, Inc's net profit margin was 13.9% in Q2 2027, showing the share of revenue converted to profit. This is down 1.0 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.9 percentage points.
Argan, Inc's ROE was 10.5% in Q2 2027, measuring profit generated per dollar of shareholder equity. This is up 1.6 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.8 percentage points.
Capital Allocation
Argan, Inc spent $6.7M on share buybacks in Q2 2027, returning capital to shareholders by reducing shares outstanding. This represents an increase of 3263.8% from the same quarter a year earlier. Against the prior quarter it is up 126.5%.
Argan, Inc invested $5.3M in capex in Q2 2027, funding long-term assets and infrastructure. This represents an increase of 210.2% from the same quarter a year earlier. Against the prior quarter it is up 116.0%.
Not reported for Q2 2027.
AGX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2710-Q | Q1'2710-Q | Q4'2610-Q | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $384.0M+61.5% | $291.0M+50.2% | $262.1M+12.7% | $251.2M-2.3% | $237.7M+4.7% | $193.7M+22.8% | $232.5M+41.3% | $257.0M+56.9% |
| Cost of Revenue | $309.8M+60.1% | $229.8M+46.6% | $196.5M+6.3% | $204.2M-4.0% | $193.5M-1.2% | $156.8M+12.2% | $184.9M+31.2% | $212.7M+47.2% |
| Gross Profit | $74.2M+67.7% | $61.1M+65.8% | $65.6M+37.8% | $46.9M+5.9% | $44.3M+42.3% | $36.9M+105.4% | $47.6M+101.5% | $44.3M+130.4% |
| SG&A Expenses | $17.4M+22.5% | $15.7M+25.5% | $17.9M+20.0% | $14.3M+2.3% | $14.2M+14.4% | $12.5M+9.6% | $14.9M+25.5% | $14.0M+23.0% |
| Operating Income | $56.8M+89.0% | $45.4M+86.5% | $47.7M+45.9% | $32.6M+7.6% | $30.1M+60.9% | $24.3M+273.4% | $32.7M+178.6% | $30.3M+285.9% |
| EBITDA | $57.5M+87.7% | $46.0M+85.2% | $48.3M+44.9% | $33.2M+7.7% | $30.6M+59.3% | $24.9M+250.3% | $33.3M+170.4% | $30.9M+265.4% |
| Income Tax | $13.6M+3663.4% | $7.7M+6.5% | $6.2M-14.9% | $9.0M-0.1% | $361K-94.1% | $7.2M+110.9% | $7.3M+46.5% | $9.0M+46.3% |
| Net Income | $53.3M+51.1% | $46.1M+104.3% | $49.2M+56.9% | $30.7M+9.7% | $35.3M+93.8% | $22.6M+186.1% | $31.4M+161.0% | $28.0M+412.6% |
| EPS (Basic) | $3.80+47.9% | $3.30+100.0% | $3.55+53.7% | $2.22+7.2% | $2.57+89.0% | $1.65+179.7% | $2.31+156.7% | $2.07+404.9% |
| EPS (Diluted) | $3.76+50.4% | $3.24+102.5% | $3.47+54.9% | $2.17+8.5% | $2.50+90.8% | $1.60+175.9% | $2.24+151.7% | $2.00+400.0% |
| Diluted Shares (Avg) | 14M+0.2% | 14M+0.6% | N/A | 14M+0.9% | 14M+1.8% | 14M+4.0% | N/A | 14M+3.5% |
Not reported in any period shown, so not listed: R&D Expenses, Interest Expense.
AGX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2710-Q | Q1'2710-Q | Q4'2610-Q | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.4B+58.7% | $1.3B+62.4% | $1.2B+41.9% | $1.1B+36.7% | $882.7M+21.5% | $792.2M+26.9% | $836.2M+39.8% | $768.9M+36.4% |
| Current Assets | $1.3B+59.1% | $1.2B+64.8% | $1.1B+44.9% | $997.2M+39.0% | $828.8M+22.8% | $738.1M+28.5% | $781.3M+42.8% | $717.1M+39.5% |
| Cash & Equivalents | $364.5M+104.9% | $355.8M+88.0% | $339.5M+133.7% | $306.3M+74.7% | $177.8M-23.6% | $189.3M-8.9% | $145.3M-26.3% | $175.3M-5.5% |
| Short-Term Investments | $183.4M+87.8% | $172.8M+50.2% | $151.9M-0.8% | $117.4M-5.7% | $97.7M+41.0% | $115.0M+36.9% | $153.1M+39.9% | $124.5M+15.2% |
| Accounts Receivable | $180.4M+0.7% | $130.8M+22.8% | $133.7M-24.0% | $170.4M+29.4% | $179.2M+88.0% | $106.5M+77.6% | $175.8M+271.5% | $131.7M+163.7% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill | $30.7M+9.4% | $28.0M0.0% | $28.0M0.0% | $28.0M0.0% | $28.0M0.0% | $28.0M0.0% | $28.0M0.0% | $28.0M0.0% |
| Total Liabilities | $894.1M+82.7% | $812.9M+89.8% | $724.1M+49.5% | $631.2M+43.4% | $489.5M+17.0% | $428.3M+29.3% | $484.4M+57.6% | $440.2M+57.9% |
| Current Liabilities | $878.1M+81.3% | $794.7M+87.9% | $711.3M+48.2% | $619.9M+42.1% | $484.3M+16.7% | $422.9M+29.1% | $479.9M+58.8% | $436.2M+59.2% |
| Non-Current Liabilities | $16.0M+207.7% | $18.2M+243.5% | $12.8M+184.4% | $11.3M+182.8% | $5.2M+54.1% | $5.3M+45.3% | $4.5M-10.3% | $4.0M-18.9% |
| Total Equity | $506.8M+28.9% | $473.5M+30.1% | $462.3M+31.4% | $419.7M+27.7% | $393.2M+27.6% | $363.9M+24.1% | $351.9M+20.9% | $328.7M+15.4% |
| Retained Earnings | $491.5M+44.5% | $445.3M+43.5% | $406.2M+38.8% | $364.0M+36.7% | $340.3M+39.7% | $310.2M+35.2% | $292.7M+29.8% | $266.3M+22.5% |
Not reported in any period shown, so not listed: Inventory, Long-Term Debt.
AGX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2710-Q | Q1'2710-Q | Q4'2610-Q | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $97.0M+180.2% | $113.4M+221.3% | $172.3M+286.2% | $172.5M+442.8% | $34.6M-52.9% | $35.3M+99.6% | $44.6M+81.4% | $31.8M-44.9% |
| Depreciation & Amortization | $720K+22.2% | $634K+23.6% | $583K-7.0% | $603K+13.6% | $589K+5.0% | $513K-11.1% | $627K+6.8% | $531K-9.5% |
| Stock-Based Compensation | $2.4M+4.3% | $2.0M+71.4% | N/A | $1.9M+58.3% | $2.3M+130.0% | $1.2M-1.9% | N/A | $1.2M0.0% |
| Capital Expenditures | $5.3M+210.2% | $2.4M+515.9% | $1.2M-11.7% | $583K-77.1% | $1.7M-27.9% | $395K+22.7% | $1.4M+122.7% | $2.5M+129.0% |
| Free Cash Flow | $91.7M+178.7% | $111.0M+217.9% | $171.1M+295.6% | $171.9M+488.1% | $32.9M-53.7% | $34.9M+101.0% | $43.3M+80.4% | $29.2M-48.4% |
| Investing Cash Flow | -$63.3M-61.5% | -$67.5M-370.8% | -$130.6M-95.6% | -$37.1M+54.9% | -$39.2M+8.6% | $24.9M+1541.9% | -$66.8M-1066.9% | -$82.3M-17.0% |
| Financing Cash Flow | -$18.1M-161.0% | -$33.6M-86.9% | -$10.1M-20.1% | -$7.5M-8.5% | -$6.9M-24.5% | -$18.0M-251.7% | -$8.4M-5.5% | -$6.9M-24.8% |
| Dividends Paid | $7.0M+35.6% | $7.0M+38.2% | $7.0M+39.4% | $7.1M+35.8% | $5.2M+28.0% | $5.1M+26.0% | $5.0M+25.2% | $5.2M+30.3% |
| Share Buybacks | $6.7M+3263.8% | $3.0M-56.9% | $2.8M+222.2% | $0-100.0% | $199K | $6.8M+3562.6% | $878K-78.0% | $459K-73.5% |
AGX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2710-Q | Q1'2710-Q | Q4'2610-Q | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 19.3%+0.7pp | 21.0%+2.0pp | 25.0%+4.6pp | 18.7%+1.4pp | 18.6%+4.9pp | 19.0%+7.6pp | 20.5%+6.1pp | 17.3%+5.5pp |
| Operating Margin | 14.8%+2.1pp | 15.6%+3.0pp | 18.2%+4.1pp | 13.0%+1.2pp | 12.6%+4.4pp | 12.6%+8.4pp | 14.1%+6.9pp | 11.8%+7.0pp |
| Net Margin | 13.9%-1.0pp | 15.8%+4.2pp | 18.8%+5.3pp | 12.2%+1.3pp | 14.8%+6.8pp | 11.6%+6.6pp | 13.5%+6.2pp | 10.9%+7.6pp |
| Return on Equity | 10.5%+1.6pp | 9.7%+3.5pp | 10.7%+1.7pp | 7.3%-1.2pp | 9.0%+3.1pp | 6.2%+3.5pp | 8.9%+4.8pp | 8.5%+6.6pp |
| Return on Assets | 3.8%-0.2pp | 3.6%+0.7pp | 4.2%+0.4pp | 2.9%-0.7pp | 4.0%+1.5pp | 2.9%+1.6pp | 3.8%+1.7pp | 3.6%+2.7pp |
| Current Ratio | 1.50-0.2x | 1.53-0.2x | 1.590.0x | 1.610.0x | 1.71+0.1x | 1.750.0x | 1.63-0.2x | 1.64-0.2x |
| Debt-to-Equity | 1.76+0.5x | 1.72+0.5x | 1.57+0.2x | 1.50+0.2x | 1.25-0.1x | 1.180.0x | 1.38+0.3x | 1.34+0.4x |
| Asset Turnover | 0.270.0x | 0.230.0x | 0.22-0.1x | 0.24-0.1x | 0.270.0x | 0.240.0x | 0.280.0x | 0.330.0x |
| FCF Margin | 23.9%+10.1pp | 38.1%+20.1pp | 65.3%+46.7pp | 68.5%+57.1pp | 13.8%-17.5pp | 18.0%+7.0pp | 18.6%+4.0pp | 11.4%-23.2pp |
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Argan, Inc AGX | FY2026 | $944.6M | $137.8M | 14.6% | $5.4B | 70/100 |
| Tutor Perini Corporation TPC | FY2025 | $5.5B | $80.4M | 1.5% | $4.4B | 55/100 |
| Everus Construction Group, Inc. ECG | FY2025 | $3.7B | $201.8M | 5.4% | $6.3B | 66/100 |
| Exponent Inc EXPO | FY2025 | $582.0M | $106.0M | 18.2% | $3.3B | 71/100 |
| MYR Group, Inc. MYRG | FY2025 | $3.7B | $118.4M | 3.2% | $4.9B | 54/100 |
| Arcosa, Inc. ACA | FY2025 | $2.9B | $208.4M | 7.2% | $7.2B | 57/100 |
Where Argan, Inc Ranks
Frequently Asked Questions
What is Argan, Inc's annual revenue?
Argan, Inc (AGX) reported $944.6M in total revenue for fiscal year 2026. This represents a 8.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Argan, Inc's revenue growing?
Argan, Inc (AGX) revenue grew by 8.1% year-over-year, from $874.2M to $944.6M in fiscal year 2026.
Is Argan, Inc profitable?
Yes, Argan, Inc (AGX) reported a net income of $137.8M in fiscal year 2026, with a net profit margin of 14.6%.
What is Argan, Inc's EBITDA?
Argan, Inc (AGX) had EBITDA of $137.0M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.
What is Argan, Inc's gross margin?
Argan, Inc (AGX) had a gross margin of 20.5% in fiscal year 2026, indicating the percentage of revenue retained after direct costs of goods sold.
What is Argan, Inc's operating margin?
Argan, Inc (AGX) had an operating margin of 14.3% in fiscal year 2026, reflecting the profitability of core business operations before interest and taxes.
What is Argan, Inc's net profit margin?
Argan, Inc (AGX) had a net profit margin of 14.6% in fiscal year 2026, representing the share of revenue converted into profit after all expenses.
Does Argan, Inc pay dividends?
Yes, Argan, Inc (AGX) paid $1.75 per share in dividends during fiscal year 2026.
What is Argan, Inc's return on equity (ROE)?
Argan, Inc (AGX) has a return on equity of 29.8% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.
What is Argan, Inc's free cash flow?
Argan, Inc (AGX) generated $410.8M in free cash flow during fiscal year 2026. This represents a 155.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Argan, Inc's operating cash flow?
Argan, Inc (AGX) generated $414.7M in operating cash flow during fiscal year 2026, representing cash generated from core business activities.
What are Argan, Inc's total assets?
Argan, Inc (AGX) had $1.2B in total assets as of fiscal year 2026, including both current and long-term assets.
What are Argan, Inc's capital expenditures?
Argan, Inc (AGX) invested $3.9M in capital expenditures during fiscal year 2026, funding long-term assets and infrastructure.
What is Argan, Inc's current ratio?
Argan, Inc (AGX) had a current ratio of 1.59 as of fiscal year 2026, which is generally considered healthy.
What is Argan, Inc's debt-to-equity ratio?
Argan, Inc (AGX) had a debt-to-equity ratio of 1.57 as of fiscal year 2026, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Argan, Inc's return on assets (ROA)?
Argan, Inc (AGX) had a return on assets of 11.6% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.
What is Argan, Inc's P/E ratio?
Argan, Inc (AGX) trades at 30.3x earnings, its market capitalization divided by net income of $179.3M net income, trailing 12 months to July 31, 2026. The market capitalization is $5.4B as of Oct 12, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Argan, Inc's price-to-sales ratio?
Argan, Inc (AGX) trades at 4.6x sales, its market capitalization divided by revenue of $1.2B revenue, trailing 12 months to July 31, 2026. The market capitalization is $5.4B as of Oct 12, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Argan, Inc's Altman Z-Score?
Argan, Inc (AGX) has an Altman Z-Score of 6.59, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Argan, Inc's Piotroski F-Score?
Argan, Inc (AGX) has a Piotroski F-Score of 5 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Argan, Inc's earnings high quality?
Argan, Inc (AGX) has an earnings quality ratio of 3.01x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Argan, Inc?
Argan, Inc (AGX) scores 70 out of 100 on our Financial Health Score, indicating strong standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.